Literature DB >> 13841546

Value of antirabies vaccine with and without serum against severe challenges.

N VEERARAGHAVAN, T P SUBRAHMANYAN.   

Abstract

Earlier studies with antirabies serum and vaccine have been extended to determine the value of serum, vaccine, or serum and vaccine combined against rabies challenges of increasing degrees of severity. While serum alone was not found to have any protective effect, vaccine alone was sufficient against mild challenges, the superiority of combined therapy with both serum and vaccine becoming evident at a challenge of about 50 LD(50). With challenges of over 300 LD(50) no treatment was of any value. It was also found that with a recommended optimum dose of serum, the usual vaccine dose could be halved-a matter of importance in countries with a high incidence of neuroparalytic accidents following administration of nervous tissue vaccine.

Entities:  

Keywords:  RABIES/immunology

Mesh:

Substances:

Year:  1960        PMID: 13841546      PMCID: PMC2555339     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  2 in total

1.  Improvement of the antigenicity of antirabies vaccine by pooling checked by post-challenge vaccination of guinea-pigs.

Authors:  N VEERARAGHAVAN
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408

2.  Advances in rabies treatment; an experimental evaluation.

Authors:  N VEERARAGHAVAN; A BALASUBRAMANIAN; T P SUBRAHMANYAN
Journal:  Bull World Health Organ       Date:  1957       Impact factor: 9.408

  2 in total
  8 in total

1.  Local application of antirabies gamma-globulin in dried form for the prevention of rabies.

Authors:  V D SOLOVIEV; G D KOBRINSKI
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

2.  Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 3.

Authors:  P ATANASIU; D A CANNON; D J DEAN; J P FOX; K HABEL; M M KAPLAN; R E KISSLING; H KOPROWSKI; P LEPINE; F PEREZ GALLARDO
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

3.  Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin.

Authors:  H Wilde; P Chomchey; P Punyaratabandhu; P Phanupak; S Chutivongse
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

4.  An allergen-free antirabies vaccine.

Authors:  G J Svet-Moldavskij; O G Andjaparidze; S S Unanov; M K Karakajumcan; I A Svet-Moldavskaja; L S Mucnik; M A Hieninson; L I Ravkina; A A Mtvarelidze; O F Volkova; M R Kriegshaber; A G Kalinkina; T V Salita; V I Klimovickaja; I N Bondaletova; V M Rojheĺ; I S Kiseleva; E N Levcenko; S S Marennikova; S L Leonidova
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

5.  DURATION OF IMMUNITY TO REINFECTION IN GUINEA-PIGS TREATED WITH ANTIRABIES SERUM AND VACCINE, AND THE VALUE OF BOOSTER DOSES OF VACCINE IN RE-TREATMENT.

Authors:  N VEERARAGHAVAN; T P SUBRAHMANYAN
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

6.  Rapidity and magnitude of antibody response to duck-embryo rabies vaccine administered as a pre-exposure regimen.

Authors:  P R Schnurrenberger; G R Anderson; J H Russell
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

7.  THE VALUE OF DUCK-EMBRYO VACCINE AND HIGH-EGG-PASSAGE FLURY VACCINE IN EXPERIMENTAL RABIES INFECTION IN GUINEA-PIGS.

Authors:  N VEERARAGHAVAN; T P SUBRAHMANYAN
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

Review 8.  Antiviral therapy.

Authors:  H Stalder
Journal:  Yale J Biol Med       Date:  1977 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.